Valuation: IXICO plc

Market Cap 20.17M 27.07M 23.68M 21.84M 38.27M 2.58B 38.91M 261M 102M 1.27B 102M 99.42M 4.37B P/E 2026 *
-6.61x
P/E 2027 * -7.12x
Enterprise Value 9.97M 13.38M 11.7M 10.79M 18.92M 1.28B 19.23M 129M 50.65M 629M 50.23M 49.14M 2.16B EV / Sales 2026 *
1.25x
EV / Sales 2027 * 1.56x
Free-Float
89.25%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 2019-08-20
Director/Board Member 60 2022-01-20
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 27.07M
+0.58%+2.06%+3.90%+10.40% 50.73B
-2.22%-1.25%+391.53%+591.38% 39.73B
-0.54%+0.39%+27.67%-3.89% 34.69B
-1.36%+0.35%+19.34%+58.83% 33.21B
+1.21%-4.58%+3.00%+37.03% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+125.61% 15.37B
+0.23%-0.58%+13.80%+19.56% 13.78B
-0.62%-3.09%+11.43%-29.93% 12.85B
Average -5.74%-0.83%+67.13%+101.12% 27.1B
Weighted average by Cap. -0.49%-0.23%+82.75%+126.14%

Financials

2026 *2027 *
Net sales 7.97M 10.7M 9.36M 8.63M 15.12M 1.02B 15.38M 103M 40.49M 503M 40.16M 39.29M 1.73B 9.04M 12.13M 10.61M 9.79M 17.16M 1.16B 17.44M 117M 45.93M 570M 45.56M 44.56M 1.96B
Net income -2.14M -2.88M -2.52M -2.32M -4.07M -274M -4.13M -27.72M -10.89M -135M -10.8M -10.56M -465M -2.8M -3.76M -3.29M -3.03M -5.31M -359M -5.4M -36.24M -14.23M -177M -14.11M -13.81M -607M
Net Debt -10.2M -13.69M -11.97M -11.04M -19.35M -1.31B -19.68M -132M -51.82M -643M -51.4M -50.28M -2.21B -6.1M -8.19M -7.16M -6.6M -11.57M -781M -11.77M -78.91M -30.99M -385M -30.74M -30.07M -1.32B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0925GBP
Average target price
0.2600GBP
Spread / Average Target
+181.08%

Annual profits - Rate of surprise